tbuckley/cabot-search huggingface dataset:
Mental Health Treatment Seeking and History of Suicidal Thoughts Among Suicide Decedents by Mechanism, 2003-2018
Authors: Allison E. Bond, Shelby L. Bandel, Taylor R. Rodriguez, Joye C. Anestis, Michael D. Anestis
Journal: JAMA Network Open (2022)

Understanding mental health and substance use treatment seeking and suicidality among suicide decedents is important to determine prevention efforts.To evaluate differences in treatment seeking and suicidality between suicide decedents who died by firearms and those who died by other methods.Cross-sectional data were collected on 234 652 suicide decedents from 2003 to 2018. Participant information was reported by their state of residence to the National Violent Death Reporting System. Statistical analysis was performed from July 1, 2021, to January 21, 2022.Main outcomes were treatment for mental health and substance use at time of death, previous treatment for mental health and substance use, history of suicidal ideation or plans, history of suicide attempts, and disclosure of suicidal ideation or plans.A total of 234 652 participants (182 520 male [77.8%]; 205 966 White [87.8%]; mean [SD] age, 46.3 [18.2] years [range, 3-112 years]) were included in this study. Compared with suicide decedents who died by another method (n = 117 526 [50.1%]), those who died by firearm (n = 117 126 [49.9%]) were more likely to have disclosed thoughts or plans of suicide within the month prior to death (odds ratio [OR], 1.16 [95% CI, 1.13-1.18]) and were less likely to have previously attempted suicide (OR, 0.44 [95% CI, 0.43-0.46]). Compared with those who died by poisoning, those who used a firearm were more likely to have had a history of suicidal thoughts or plans (OR, 1.19 [95% CI, 1.15-1.23]) and to have disclosed their thoughts or plans of suicide within the month prior to death (OR, 1.06 [95% CI, 1.03-1.10]). Compared with those who died by hanging, those who used a firearm were more likely to have disclosed their thoughts or plans of suicide to another person within the month prior to their death (OR, 1.14 [95% CI, 1.11-1.17]).These findings provide information that suggests who is at risk to die by firearm suicide. Community-based interventions in suicide prevention could help reduce access to firearms during a time of crisis. The finding that firearm suicide decedents were more likely to disclose their suicidal thoughts or plans provides an important avenue for prevention.
Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients
Authors: Wen Zhang, Caifeng Gong, Xuenan Peng, Xinyu Bi, Yongkun Sun, Jianguo Zhou, Fan Wu, Huiying Zeng, Yan Wang, Hui Zhou, Hong Zhao, Jianqiang Cai, Aiping Zhou
Journal: Clinical Cancer Research (2022)

Abstract Purpose: This study aimed to investigate the biomarkers of sintilimab (anti–PD-1) plus IBI305 (a bevacizumab biosimilar) in advanced hepatocellular carcinoma (HCC), as well as their safety and efficacy. Patients and Methods: A total of 50 patients with advanced HCC received sintilimab (200 mg) plus IBI305 (7.5 or 15 mg/kg), treated every 3 weeks in a phase Ib clinical study. We performed baseline serum cytokine analysis using bead-based multiplex immunoassay and multiplex immunofluorescence on tissue specimens to discover novel biomarkers of response to VEGF/PD-1 combination therapy in HCC. Results: The overall response rate was 34.0% (17/50). The median progression-free survival (PFS) and the median overall survival were 10.5 and 20.2 months, respectively. The incidence of grade 3 to 5 adverse events was lower in the 7.5 mg/kg (13.8%) than in the 15 mg/kg (28.6%) dose groups. Biomarker analysis showed that the serum CD137 concentration was significantly higher in patients with clinical benefit (CB) than in those without CB (median, 32.8 pg/mL vs. 19.8 pg/mL, P = 0.034). A markedly longer PFS was observed in patients with high CD137 concentrations compared with those with low concentrations (median, 14.2 months vs. 4.1 months, P = 0.001). The higher density of M1 macrophages (CD68+CD163–) in the stroma was also associated with higher efficacy (P = 0.033) and a longer PFS (P = 0.024). Conclusions: Sintilimab plus IBI305 was well tolerated and was effective therapy for advanced HCC. Both serum concentrations of CD137 and tumor infiltration of M1 macrophages may serve as potential predictive biomarkers. See related commentary by Cappuyns and Llovet, p. 3405
Long non-coding RNA LINC00680 functions as a ceRNA to promote esophageal squamous cell carcinoma progression through the miR-423-5p/PAK6 axis
Authors: Song-tao Xue, Bin Zheng, Shi-qiang Cao, Jian-cheng Ding, Guo-sheng Hu, Wen Liu, Chun Chen
Journal: Molecular Cancer (2022)

Abstract Background Esophageal squamous cell carcinoma (ESCC) is a common invasive malignancy worldwide with poor clinical outcomes. Increasing amount of long non-coding RNAs (lncRNAs) have been reported to be involved in cancer development. However, lncRNAs that are functional in ESCC and the underlying molecular mechanisms remain largely unknown. Methods Transcriptomic analysis was performed to identify dysregulated lncRNAs in ESCC tissue samples. The high expression of LINC00680 in ESCC was validated by RT-qPCR, and the oncogenic functions of LINC00680 was investigated by cell proliferation, colony formation, migration and invasion assays in ESCC cells in vitro and xenografts derived from ESCC cells in mice. RNA-seq, competitive endogenous RNA (ceRNA) network analysis, and luciferase reporter assays were carried out to identify LINC00680 target genes and the microRNAs (miRNAs) bound to LINC00680. Antisense oligonucleotides (ASOs) were used for in vivo treatment. Results Transcriptome profiling revealed that a large number of lncRNAs was dysregulated in ESCC tissues. Notably, LINC00680 was highly expressed, and upregulation of LINC00680 was associated with large tumor size, advanced tumor stage, and poor prognosis. Functionally, knockdown of LINC00680 restrained ESCC cell proliferation, colony formation, migration, and invasion in vitro and inhibited tumor growth in vivo. Mechanistically, LINC00680 was found to act as a ceRNA by sponging miR-423-5p to regulate PAK6 (p21-activated kinase 6) expression in ESCC cells. The cell viability and motility inhibition induced by LINC00680 knockdown was significantly reversed upon PAK6 restoration and miR-423-5p inhibition. Furthermore, ASO targeting LINC00680 substantially suppressed ESCC both in vitro and in vivo. Conclusions An oncogenic lncRNA, LINC00680, was identified in ESCC, which functions as a ceRNA by sponging miR-423-5p to promote PAK6 expression and ESCC. LINC00680/miR-423-5p/PAK6 axis may serve as promising diagnostic and prognostic biomarkers and therapeutic targets for ESCC.
MITRAL VALVE ENDOCARDITIS DUE TO STREPTOCOCCUS GALLOLYTICUS SUBSPECIES PASTEURIANUS IN AN IMMUNOCOMPETENT PATIENT WITH A NORMAL HEART AND SPLENIC ABSCESSES AS A COMPLICATION
Authors: Maria R. Cochran-Perez, Ubaldo Madera Sanchez, Oscar A. Rodriguez-Ayala, Angel J. Ruiz Vera
Journal: Journal of the American College of Cardiology (2022)
Lung function from school age to adulthood in primary ciliary dyskinesia
Authors: Florian S. Halbeisen, Eva S.L. Pedersen, Myrofora Goutaki, Ben D. Spycher, Israel Amirav, Mieke Boon, Malena Cohen-Cymberknoh, Suzanne Crowley, Nagehan Emiralioglu, Eric G. Haarman, Bulent Karadag, Cordula Koerner-Rettberg, Philipp Latzin, Michael R. Loebinger, Jane S. Lucas, Henryk Mazurek, Lucy Morgan, June Marthin, Petr Pohunek, Francesca Santamaria, Nicolaus Schwerk, Guillaume Thouvenin, Panayiotis Yiallouros, Kim G. Nielsen, Claudia E. Kuehni
Journal: European Respiratory Journal (2022)

Primary ciliary dyskinesia (PCD) presents with symptoms early in life and the disease course may be progressive, but longitudinal data on lung function are scarce. This multinational cohort study describes lung function trajectories in children, adolescents and young adults with PCD. We analysed data from 486 patients with repeated lung function measurements obtained between the age of 6 and 24 years from the International PCD Cohort and calculated z-scores for forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC) and FEV1/FVC ratio using the Global Lung Function Initiative 2012 references. We described baseline lung function and change of lung function over time and described their associations with possible determinants in mixed-effects linear regression models. Overall, FEV1, FVC and FEV1/FVC z-scores declined over time (average crude annual FEV1 decline was -0.07 z-scores), but not at the same rate for all patients. FEV1 z-scores improved over time in 21% of patients, remained stable in 40% and declined in 39%. Low body mass index was associated with poor baseline lung function and with further decline. Results differed by country and ultrastructural defect, but we found no evidence of differences by sex, calendar year of diagnosis, age at diagnosis, diagnostic certainty or laterality defect. Our study shows that on average lung function in PCD declines throughout the entire period of lung growth, from childhood to young adult age, even among patients treated in specialised centres. It is essential to develop strategies to reverse this tendency and improve prognosis.
DOUBLE BEATS LEAD TO DOUBLE TROUBLE
Authors: Syed Rafay Ali Sabzwari, James Mann, Christopher Barrett, Lukasz Patrick Cerbin, Amneet Sandhu, Paul D. Varosy, John Jason West, Lohit Garg, Alexis Z. Tumolo, Michael Rosenberg, Ryan G. Aleong, Matthew Michael Zipse, Wendy S. Tzou
Journal: Journal of the American College of Cardiology (2022)
CLINICAL IMPORTANCE OF GLOBAL ISCHEMIA ASSESSMENT IN STABLE CORONARY ARTERY DISEASE BASED ON A NOVEL ANGIOGRAPHY-BASED INDEX
Authors: Ka Lam Calvin Leung, Lok Yee Lam, Kwan Yu Li, Shuk Yin Yu, Mei Zhen Wu, Qing Wen Ren, Pui Fai Wong, Yi Kei Tse, Si Yeung Yu, Hang Long Li, Yundi Feng, Yunlong Huo, Hung-Fat Tse, Kai Hang Yiu
Journal: Journal of the American College of Cardiology (2022)
More on BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
Authors: Emmanuel B Walter, Kawsar R Talaat, Alejandra Gurtman
Journal: New England Journal of Medicine (2022)

To the Editor: Walter et al. (Jan.6 issue) 1 report that the BNT162b2 Covid-19 vaccine was safe and effective in children between 5 and 11 years of age. 1 In the midst of successive waves of SARS-CoV-2 variants, the B.1.1.529(omicron) variant has recently caused a surge in pediatric infections and hospitalizations. 2 In France, the shift from the B.1.617.2 (delta) variant to omicron began in mid-December 2021.So far, omicron is considered to be more contagious than the delta variant, but data are needed on its severity in children.The omicron variant is thought to lead to less severe forms of Covid-19 in adults, a reduction that has been at least partly attributed to the widespread receipt of Covid-19 vaccines. 3,4 In our pediatric pulmonology unit, hospitalizations for SARS-CoV-2 infection have more than doubled between the waves of the delta variant (mid-November to mid-December) and the arrival of the omicron variant (from mid-December to mid-January).During the omicron wave, hospitalized children had fewer preexisting conditions than did those during the delta wave, as well as slightly different symptoms at infection onset (Table 1).Only one infection in an asthmatic infant (aged 15 months) resulted in admission to the intensive care unit for acute respiratory distress.None of the hospitalized children who were 12 years of age or older had been fully vaccinated.This report emphasizes the importance of rapidly expanding vaccination against Covid-19 in children who are older than 5 years of age.
Table of Contents
Authors: Moawia Mohammed, Ali Elhassan, Rad Onc, Ahmed Abdalla Mohamedani, Sahar Abdelrahman, Hamid Mohamed, Anas Osman, Ahmed Hamdoun, Omer Abuidris, Alsideeg Mohammed, Alamin Mohammed, Khalid Awadelkarim, Lizza Hendriks, Jordi Remon, Martin Reck, Samuel Rosner, Patrick Forde, Joseph Maleszewski, Cristina Basso, Melanie Bois, Carolyn Glass, Kyle Klarich, Charles Leduc, Robert Padera, Fabio Tavora
Journal: Journal of Thoracic Oncology (2022)
THE LESSER KNOWN ANOMALOUS CORONARY: AN INCIDENTAL FINDING OF ANOMALOUS RIGHT CORONARY ARTERY FROM THE PULMONARY ARTERY (ARCAPA)
Authors: Sara Sadat-Hossieny, Justin Jin, Mandi Bolibrush, Rukmini Komarlu, Christina Fink, Rula S. Balluz
Journal: Journal of the American College of Cardiology (2022)
DMPC/Chol liposomal copper CX5461 is therapeutically superior to a DSPC/Chol formulation
Authors: Ada W.Y. Leung, Kent T.J. Chen, Gemma M. Ryan, Malathi Anantha, Nicole Wretham, Zeynab Nosrati, Devon Heroux, Linchuan Wang, Norman Chow, Zhongye Dai, Marcel B. Bally
Journal: Journal of Controlled Release (2022)

CX5461, a compound initially identified as an RNA polymerase inhibitor and more recently as a G-quadruplex binder, binds copper to form a complex. Our previous publication showed that the complexation reaction can be leveraged to formulate copper-CX5461 inside liposomes, improving the apparent solubility of CX5461 by over 500-fold and reducing the elimination of CX5461 from the plasma compartment following intravenous administration. In mouse models of acute myeloid leukemia, the resulting formulation was more effective than the free drug solution of CX5461 (pH 3.5) currently used in clinical trials. However, the gains observed with the liposomal formulation were minimal, despite significant increases in circulation half-life. Since the formulation technology used relied on liposomes and the fate of most compounds associated with liposomes is dependent on liposomal lipid composition, the studies described here were designed to evaluate how simple changes in lipid composition could affect therapeutic activity. The previously reported formulation method was simplified to ensure an easy scale-up process. In the modified method, pre-measured solid CX5461 was added to copper-containing liposomes prior to an incubation at 60 °C, which enabled copper-CX5461 complexation inside DSPC/Chol or DMPC/Chol liposomes. Efficacy was determined in BRCA-normal (BxPC3) and BRCA-deficient (Capan-1) models of pancreatic cancer. Both liposomal formulations enhanced the circulation lifetime of CX5461 compared to the free drug solution (pH 3.5). Unlike most compounds that are loaded using a transmembrane pH-gradient, the dissociation of CX5461 from liposomes prepared using the copper complexation method were comparable for DSPC/Chol and DMPC/Chol liposomes, in vitro and in vivo. Nonetheless, copper CX5461 prepared using DMPC/Chol liposomes exhibited superior efficacy. The reason for the improved activity of DMPC/Chol copper-CX5461 was not readily explained by the release data and may be due to the fact that DMPC/Chol liposomes are less stable following localization in the tumor. The results indicate that the therapeutic effects of copper-CX5461 will be dependent on liposomal lipid composition and that liposomal CX5461 should exhibit superior benefits when used to treat BRCA-deficient cancers.
CARDIOVASCULAR OUTCOMES WITH FINERENONE ACCORDING TO STATUS OF GLYCEMIA AT BASELINE AND PRIOR TREATMENT WITH NEWER ANTIDIABETIC REGIMENS AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS
Authors: Dimitrios Patoulias, Christodoulos Papadopoulos, Aristi Boulmpou, Nikolaos Fragakis, Vassilios P. Vassilikos, Michail Doumas
Journal: Journal of the American College of Cardiology (2022)
Type 1 conventional dendritic cells maintain and guide the differentiation of precursors of exhausted T cells in distinct cellular niches
Authors: Sabrina Dähling, Ana Maria Mansilla, Konrad Knöpper, Anika Grafen, Daniel T. Utzschneider, Milas Ugur, Paul G. Whitney, Annabell Bachem, Panagiota Arampatzi, Fabian Imdahl, Tsuneyasu Kaisho, Dietmar Zehn, Frederick Klauschen, Natalio Garbi, Axel Kallies, Antoine-Emmanuel Saliba, Georg Gasteiger, Sammy Bedoui, Wolfgang Kastenmüller
Journal: Immunity (2022)
Early administration of <scp>COVID</scp>‐19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy
Authors: Artur Belov, Yin Huang, Carlos H. Villa, Barbee I. Whitaker, Richard Forshee, Steven A. Anderson, Anne Eder, Nicole Verdun, Michael J. Joyner, Scott R. Wright, Rickey E. Carter, Deborah T. Hung, Mary Homer, Corey Hoffman, Michael Lauer, Peter Marks
Journal: American Journal of Hematology (2022)

The efficacy of COVID-19 convalescent plasma (CCP) as a treatment for hospitalized patients with COVID-19 remains somewhat controversial; however, many studies have not evaluated CCP documented to have high neutralizing antibody titer by a highly accurate assay. To evaluate the correlation of the administration of CCP with titer determined by a live viral neutralization assay with 7- and 28-day death rates during hospitalization, a total of 23 118 patients receiving a single unit of CCP were stratified into two groups: those receiving high titer CCP (>250 50% inhibitory dilution, ID50; n = 13 636) or low titer CCP (≤250 ID50; n = 9482). Multivariable Cox regression was performed to assess risk factors. Non-intubated patients who were transfused with high titer CCP showed 1.1% and 1.7% absolute reductions in overall 7- and 28-day death rates, respectively, compared to those non-intubated patients receiving low titer CCP. No benefit of CCP was observed in intubated patients. The relative benefit of high titer CCP was confirmed in multivariable Cox regression. Administration of CCP with high titer antibody content determined by live viral neutralization assay to non-intubated patients is associated with modest clinical efficacy. Although shown to be only of modest clinical benefit, CCP may play a role in the future should viral variants develop that are not neutralized by other available therapeutics.
Asthma remission: what is it and how can it be achieved?
Authors: Dennis Thomas, Vanessa M. McDonald, Ian D. Pavord, Peter G. Gibson
Journal: European Respiratory Journal (2022)

Asthma treatment goals currently focus on symptom and exacerbation control rather than remission. Remission is not identical to cure, but is a step closer. This review considers the current definitions of remission in asthma, the prevalence and predictors, the pathophysiology of remission, the possibility of achieving it using the available treatment options, and the future research directions. Asthma remission is characterised by a high level of disease control, including the absence of symptoms and exacerbations, and normalisation or optimisation of lung function with or without ongoing treatment. Even in those who develop a symptomatic remission of asthma, persistent pathological abnormalities are common, leading to a risk of subsequent relapse at any time. Complete remission requires normalisation or stabilisation of any underlying pathology in addition to symptomatic remission. Remission is possible as part of the natural history of asthma, and the prevalence of remission in the adult asthma population varies between 2% and 52%. The factors associated with remission include mild asthma, better lung function, better asthma control, younger age, early-onset asthma, shorter duration of asthma, milder bronchial hyperresponsiveness, fewer comorbidities and smoking cessation or never smoking. Although previous studies have not targeted treatment-induced remission, there is some evidence to show that the current long-term add-on therapies such as biologics and azithromycin can achieve some criteria for asthma remission on treatment, at least in a subgroup of patients. However, more research is required. Long-term remission could be included as a therapeutic goal in studies of asthma treatments.
VICIOUS CYCLE OF STENT THROMBOSIS: SIX CORONARY CATHETERIZATIONS LATER
Authors: Prem Patel, Nirmal Guragai, Kalpeshkumar Shah, Rachel Abboud, George Horani, Ashoke Agarwal, Emile F. Doss, Naser R. Mohammad, Mahesh Bikkina, Fayez E. Shamoon
Journal: Journal of the American College of Cardiology (2022)
THE “RIGHT WAY” TO APPROACH THE RIGHT VENTRICULAR OUTFLOW TRACT IN A PATIENT WITH HETEROTAXY SYNDROME AND INTERRUPTED INFERIOR VENA CAVA
Authors: Syed Rafay Ali Sabzwari, Shu Chang, James Mann, Lukasz Patrick Cerbin, Christopher Barrett, John Jason West, Paul D. Varosy, Lohit Garg, Michael Rosenberg, Ryan G. Aleong, Amneet Sandhu, Wendy S. Tzou, Matthew Michael Zipse, Alexis Z. Tumolo
Journal: Journal of the American College of Cardiology (2022)
ASSESSMENT OF ATHEROTHROMBOTIC RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Authors: David Berg, Filipe A. Moura, Minao Tang, Benjamin M. Scirica, Stephen Wiviott, David A. Morrow, Deepak L. Bhatt, Itamar Raz, Erin Ann Bohula, Robert P. Giugliano, Jeong-Gun Park, Mark William Feinberg, Eugene Braunwald, Marc Steven Sabatine
Journal: Journal of the American College of Cardiology (2022)
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study
Authors: Adam S Lauring, Mark W Tenforde, James D Chappell, Manjusha Gaglani, Adit A Ginde, Tresa McNeal, Shekhar Ghamande, David J Douin, H Keipp Talbot, Jonathan D Casey, Nicholas M Mohr, Anne Zepeski, Nathan I Shapiro, Kevin W Gibbs, D Clark Files, David N Hager, Arber Shehu, Matthew E Prekker, Heidi L Erickson, Matthew C Exline, Michelle N Gong, Amira Mohamed, Nicholas J Johnson, Vasisht Srinivasan, Jay S Steingrub, Ithan D Peltan, Samuel M Brown, Emily T Martin, Arnold S Monto, Akram Khan, Catherine L Hough, Laurence W Busse, Caitlin C ten Lohuis, Abhijit Duggal, Jennifer G Wilson, Alexandra June Gordon, Nida Qadir, Steven Y Chang, Christopher Mallow, Carolina Rivas, Hilary M Babcock, Jennie H Kwon, Natasha Halasa, Carlos G Grijalva, Todd W Rice, William B Stubblefield, Adrienne Baughman, Kelsey N Womack, Jillian P Rhoads, Christopher J Lindsell, Kimberly W Hart, Yuwei Zhu, Katherine Adams, Stephanie J Schrag, Samantha M Olson, Miwako Kobayashi, Jennifer R Verani, Manish M Patel, Wesley H Self
Journal: BMJ (2022)

To characterize the clinical severity of covid-19 associated with the alpha, delta, and omicron SARS-CoV-2 variants among adults admitted to hospital and to compare the effectiveness of mRNA vaccines to prevent hospital admissions related to each variant.
LEFT VENTRICULAR EJECTION FRACTION TEMPORAL TREND ASSOCIATION WITH MYOCARDIAL PERFUSION AND LEFT VENTRICULAR REMODELING ASSESSED WITH CARDIAC MAGNETIC RESONANCE IMAGING: RESULTS FROM THE WOMEN’S ISCHEMIA SYNDROME EVALUATION - CORONARY VASCULAR DYSFUNCTION PROJECT
Authors: Joanne Michelle D. Gomez, Marie Lauzon, Okezi Obrutu, Jenna Maughan, Michael D. Nelson, Chrisandra Shufelt, Eileen M. Handberg, Carl J. Pepine, Janet Wei, C. Noel Bairey Merz
Journal: Journal of the American College of Cardiology (2022)
BETA BLOCKER THERAPY BLUNTS THE BLOOD PRESSURE LOWERING EFFECT OF ATRIAL PACING IN HYPERTENSIVE PATIENTS: A POSSIBLE CONFIRMATION OF THE SYMPATHOLYTIC EFFECT OF PACING.
Authors: Eli S. Gang, Robert Develle, Armando SanVicente, Bich-Lien Nguyen, Michael Howard Burnam
Journal: Journal of the American College of Cardiology (2022)